Gardasil is a non-infectious quadrivalent recombinant
vaccine, which delivers the major capsid (L1) protein of human papillomavirus
(HPV) types 6, 11, 16 and 18 in highly purified virus-like particles, in
combination wth an aluminum-containing vaccine adjuvant.
Gardasil is specifically indicated for the prevention of conditions caused by
HPV types 6, 11, 16 and 18 infections. These include cervical cancer, genital
warts (condyloma acuminata), and precancerous or dysplastic lesions (including
cervical adenocarcinoma in situ (AIS), cervical intraepithelial neoplasia (CIN)
grades 1 and 2/3, vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3,
and vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3).
Gardasil is supplied as a white, cloudy liquid for intramuscular injection. The
recommended dosing regimen is 3 single injections of 0.5 ml of the vaccine, at
day 0, 2 months after the first dose, and 6 months after the first dose.
More information is available at